• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of a novel treatment toward prevention of HTLV-1 transmission and ATL disease onset

Research Project

Project/Area Number 20K17402
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 54010:Hematology and medical oncology-related
Research InstitutionThe University of Tokushima

Principal Investigator

HARADA Takeshi  徳島大学, 大学院医歯薬学研究部(医学域), 准教授 (10618359)

Project Period (FY) 2020-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2021: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2020: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords成人T細胞白血病リンパ腫 / NF-kB / PIM1 / 血液腫瘍学 / HTLV-1 / TAK1
Outline of Research at the Start

成人T細胞性白血病/リンパ腫(ATL)は現在も尚治癒がもたらされず、極めて予後不良である。治療成績の向上のためには、治療抵抗性を克服する新規標的治療を開発するとともに、HTLV-1キャリアからのHTLV-1感染増幅にともなうATLへの進展防止が必要である。本研究では、ATL細胞で活性化している多岐にわたる生存シグナル経路の枢軸的媒介因子で、ATL細胞で高発現しているセリンスレオニンキナーゼTAK1とPIM1に着目し、ATLに対する新規治療標的としての有用性とともに、HTLV-1の細胞間感染伝播の拡大と、感染細胞の増殖/不死化、dormancyやsenescenceへの役割を明らかにする。

Outline of Final Research Achievements

Adult T cell leukemia/lymphoma (ATL) cells constitutively activate NF-kB signaling pathway. Inhibition of the signaling or gene suppression of the transcription factor (TF) RELA, which is the pivotal TF in the signaling, induced apoptosis and downregulated PIM1 expression in ATL cells. PIM1 suppression/ a PIM inhibitor PIM447 induced apoptosis and downregulated RelA and TF c-MYB in protein levels but not mRNA levels. Puromycin incorporation assay demonstrated that PIM-kinase inhibition blocked translation in ATL cells. Furthermore, an Akt inhibitor MK-2206 cooperatively induced cytotoxicity in combination with PIM447 against ATL cells, suggesting PIM kinases and PI3K/Akt signaling both regulate a protein synthesis axis in ATL cells. Taken together, our findings are further warranted on the effect of blockade of protein synthesis for the prevention of ATL disease onset and HTLV-1 transmission.

Academic Significance and Societal Importance of the Research Achievements

NF-kB経路とPIM1の関係を中心にATLに対する治療標的の探索を行い、PIM阻害薬とAkt阻害薬によるタンパク質合成経路の阻害が、ATL細胞において、NF-kB経路の制御因子を含む転写因子の発現を低下させ、アポトーシスを誘導できる結果を見出した。本研究成果は、ATL研究において未だ未開発で、ATL治療開発を促進できる可能性があり、学術的意義は大きい。また、HTLV-1ウイルス感染伝播やATL発症に関する研究にも裾野を拡げていく予定であり、社会的意義は今後大きくなると期待できる。

Report

(3 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • Research Products

    (3 results)

All 2021 2020

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (2 results)

  • [Journal Article] Myeloma-Bone Interaction: A Vicious Cycle via TAK1-PIM2 Signaling2021

    • Author(s)
      1. Harada T, Hiasa M, Teramachi J, Abe M
    • Journal Title

      Cancers

      Volume: 13 Issue: 17 Pages: 4441-4441

    • DOI

      10.3390/cancers13174441

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] Efficacious therapeutic potential of targeting PIM kinases in ATL2021

    • Author(s)
      Oura M, Harada T, Teramachi J, Nakayama A, Oda A, Inoue Y, Sogabe K, Sumitani R, Fujii S, Nakamura S, Miki H, Kagawa K, Hasegawa H, Fujiwara H, Abe M
    • Organizer
      The 83rd Annual Meeting of the Japanese Society of Hematology
    • Related Report
      2021 Annual Research Report
  • [Presentation] Critical roles of the TAK1-c-Myc loop as a novel therapeutic target for ATL2020

    • Author(s)
      Oura M, Harada T, Teramachi J, Oda A, Inoue Y, Sogabe K, Sumitani R, Fujii S, Nakamura S, Miki H, Kagawa K, Hasegawa H, Fujiwara H, Abe M
    • Organizer
      The 82nd Annual Meeting of the Japanese Society of Hematology
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi